A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 208 participants.
Also called NCT05063253
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 208 participants
- Registry
-
NCT05063253
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05063253. Randomized; quadruple masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2024-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TG103
- Intervention (Drug)
- Placebo
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05063253- Content hash
046827267b75f69bd5af680e62a521038f45a4513b4585adc34e270e32df5d29